% | $
Quotes you view appear here for quick access.

Lpath Inc. Message Board

  • nyr1647 nyr1647 Feb 14, 2013 8:11 PM Flag

    google lifesciences report

    some real real good stuff from prominent analyst

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "It is very rare to see a $60M market cap company with all the positive attributes LPTN has." (2/14/13) Lpath Inc. - The Life Sciences Report interview with Ram Selvaraju

      • 1 Reply to nyr1647
      • no comments on this article .... here's a sample

        We spoke about Lpath Inc. (LPTN:NASDAQ) in our last interview. I found it to be an extremely interesting story. Your target price is $40, which would make this a $400M market cap company. It would be a major grand slam for investors. It is the largest implied return in your coverage, I think. Could you address it today?

        RS: We have been fans of Lpath for a long time, though we have been dissatisfied with the pace at which it has progressed through its phase 2 proof-of-concept clinical development program with its lead product candidate, Isonep (sonepcizumab). This is for wet age-related macular degeneration (AMD), a massive unmet need; the target is sphingosine-1-phosphate (S1P).

        But that program is now solidly back on track. We expect positive data to read out from its Nexus phase 2 study in H1/14, which is six to nine months behind the original schedule. At the end of the day we don't think it's a meaningful delay. Lpath's partner, Pfizer, remains very committed.

2.88+0.10(+3.60%)Oct 21 4:00 PMEDT